Europe

As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.

Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.

The device is most likely to be used in optogenetics, where light is used to stimulate cellar activity. It may also have functionality for monitoring tissues and cells during medical procedures.

The FDA approved Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, Rozlytrek secured accelerated approval for the treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

InflaRx reported financial and operating results for the second quarter ended June 30, 2019.

Evotec SE reported financial results and corporate updates for the first half of 2019.

According to a regulatory filing, Saunders will walk away with $14.9 million in cash and $23.6 million in equity, mostly stock based on performance.

Mallinckrodt’s experimental drug terlipressin hit the mark in a late-stage liver disease trial. Mallinckrodt said terlipressin met its primary endpoint in reversing three components of hepatorenal syndrome type 1.

Akari Therapeutics, Plc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients.

Company Outlines Roadmap to Develop Successful Therapies for Neurodegenerative Diseases Based on its Broad Anti-Tau Clinical Pipeline